羟苯磺酸钙联合厄贝沙坦治疗慢性肾脏病的临床分析

目的观察羟苯磺酸钙联合厄贝沙坦治疗慢性肾脏病（CKD）3-4期的疗效。方法选择CKD3～4期患者95例，随机分为3组，即对照组（A组）31例、厄贝沙坦组（B组）32例、羟苯磺酸钙联合厄贝沙坦组（c组）32例。疗程共3个月。观察治疗前后尿素氮（BUN）、血肌酐（SCr）、尿酸（UA）、血清胱抑素C（Cyc）、血钾、内生肌酐清除率（Ccr）、24h尿蛋白定量等各指标的变化情况。结果治疗后第3个月B、C组24h尿蛋白定量均减少，与A组比较均有统计学差异（P〈0．05）；C组减少更为显著，与B组比较有统计学差异（P〈0．05）。C组治疗后SCr明显下降，与A、B组比较均有统计学差异（P〈0．05）。结论羟苯磺酸钙联合厄贝沙坦治疗能有效降低SCr，减少尿蛋白，具有良好的肾脏保护作用，是CKD3～4期的有效治疗方案。

The curative effectiveness of calcium dobesilate combined with irbesartan in the treatment of chronic kidney disease

Objective To observe the therapeutic effectiveness of calcium dobesilate combined with irbesartan for chronic kidney disease （CKD 3-4 stage）. Methods Ninety-five chronic glomerulo- nephritis pattents accompanied with CKD 3-4 stage were randomly divided into three groups： control group （group A）, irbesartan group （group B）, calcium dobesilate combined with irbesartan group （group C）. The course of treatment was three months. Blood urea nitrogen （BUN）, serum creatinine （SCr）, uric acid, cystain C（Cyc）, blood potassium, endogenous creatinine clearance rate （Ccr）, 24-h u- rinary protein （Up） were all examined before and after the treatment. Results After the treatment for three months, Up was decreased significantly in groups B and C as compared with group A （P〈0. 05）, especially in group C. There was also statistically significant difference between groups B and C. In the group C, SCr was decreased compared to that before therapy（P〈0. 05）, and that was also significantly lower than in groups A and B in the corresponding period（P〈0. 05）. Conclusions Calcium dobesilate combined with irbesartan could reduce the serum creatinine and 24-h urinary protein. They had favorable renal protective effect and could be a good treatment protocol for chronic glomerulonephritis accompanied with CKD 3-4 stage.